Osteosarcoma Research Portal logoOsteosarcoma Research Portal

Mifamurtide (Mepact)

. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.

← All drugs · Search the portal

Facts

Topic Fact Source (access date)
First approval EU centralised authorisation 6 Mar 2009 (holder now Esteve Pharmaceuticals S.A.), about 17 years EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026)
Mechanism Synthetic version of part of a bacterial cell wall, in fat bubbles (liposomes); activates monocytes and macrophages (white blood cells) EMA EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/mepact (via entries.json)
Use in osteosarcoma Ages 2 to 30, high-grade, non-metastatic, after complete surgical removal, with chemotherapy; twice a week for 12 weeks then weekly for 24 weeks (48 infusions over 36 weeks), each a one-hour infusion EMA EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/mepact (accessed 4 Nov 2026)
Combined with Post-operative chemotherapy (in INT-0133, MAP with or without ifosfamide) doi:10.1200/JCO.2008.14.0095 (accessed 3 Nov 2026)
Results INT-0133, 678 patients: 6-year overall survival 70% to 78% (P=.03); event-free survival 61% to 68% (entries.json) doi:10.1200/JCO.2008.14.0095 (PMID 18235123)
Side effects More than 1 in 10 include fever, chills, tiredness, headache, dizziness, nausea, vomiting, fast heartbeat, high or low blood pressure, breathlessness, muscle pain, anaemia EMA EPAR Mepact (accessed 4 Nov 2026)
Owner IDM Pharma held the EU authorisation in 2009; Takeda completed acquisition of IDM on 24 Jun 2009; EU holder now Esteve Pharmaceuticals S.A. Not generic Takeda release via SEC, https://www.sec.gov/Archives/edgar/data/822206/000110465909040297/a09-16803_2ex99d2.htm (accessed 4 Nov 2026); EMA EPAR (accessed 4 Nov 2026)
Regulatory EU: authorised 2009. UK: PL 08498/0043; NICE TA235 recommends ages 2 to 30. US: FDA not-approvable letter 2007, orphan designation 2001 only. China: no approval record found entries.json (portal export), sources opened 31 Oct to 3 Nov 2026; FDA https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=143401; Level 2 facts table (4 Nov 2026)
Trials now SARCOME13 (France, high-risk), MEMOS (UK, advanced), Dragonfly v sorafenib (NCT07787429) entries.json (portal export), sources opened 31 Oct to 3 Nov 2026
Debate ESMO 2021: no consensus on use; not reimbursed in all European countries doi:10.1016/j.annonc.2021.08.1995 (via treatment_by_country.md)

Hypotheses and open points (not established fact)